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Summary:
This study compares allogeneic BMT with conventional
chemotherapy for childhood ALL in second remission.
Seventy-five children were transplanted between July
1981 and December 1995. For each patient two control
patients matching the following criteria were selected
from the Nordic database of ALL: (1) time of diagnosis,
(2) T vs non-T ALL, (3) site of relapse, (4) initial risk
group, (5) sex and (6) relapse , or >6 months after
cessation of therapy. The minimal time of follow-up was
24 months. Mortality rate in CR2, leukemic relapse rate
and the proportion in continued second remission were
16/75 (21%), 22/75 (29%) and 37/75 (50%), respectively.
P2.-EFS for the BMT group was significantly better
than that for the control group (0.40 vs 0.23, P = 0.02).
Children transplanted for bone marrow relapses in
particular had a higher P2.-EFS (0.35 vs 0.15 for the
control group, P , 0.01). Also, children grafted for
early BM relapses had a higher P2.-EFS (0.32 vs 0.11
for the control group P = 0.01). The outcome was simi-
lar when children were transplanted after early or late
relapse. Also, there was no difference in outcome
between the BMT and the chemotherapy group for chil-
dren with late relapses. We conclude that allogeneic
BMT with an HLA-identical sibling donor or other fam-
ily donor should be performed in children relapsing in
bone marrow during therapy or within 6 months of
discontinuing therapy.
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Today, modern multiagent chemotherapy is expected to
cure 70–80% of children with acute lymphoblastic leuke-
mia. However about 25–40% of children with ALL will
still experience recurrent disease after which the chance of
long-term survival and cure is considerably reduced.1
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A second remission will be induced in about 80% of
patients but a new relapse will occur in 50–90% of children
depending on site and time point of the first relapse.2–7
There is no general agreement regarding post-relapse
therapy although allogeneic bone marrow transplantation
(BMT) is commonly recommended.8,9 This treatment has
resulted in long-term disease-free survival of 30–60% of
transplanted children in a number of smaller single-insti-
tution, non-randomised studies.10–17 The impact of BMT
has, however, not been studied in strictly randomised stud-
ies comparing BMT with continuous chemotherapy.
Because BMT is generally considered superior to chemo-
therapy after first relapse of childhood ALL and the chance
of finding an HLA-identical sibling donor is small18 ran-
domised studies will be very difficult to conduct. Therefore,
case–control studies with controls carefully matched for the
important prognostic variables may form a basis for setting
up guidelines for BMT in patients with relapsed ALL.
We have employed the matched case–control method in
a previous study of BMT for very high risk ALL in first
remission.19
The purpose of the present study was to evaluate the
outcome of childhood ALL in second remission after BMT
with sibling or family donors as compared with conven-
tional chemotherapy in a retrospective case control study
utilizing the population-based Nordic ALL database.
Patients and methods
Since July 1981 the five Nordic countries (Denmark, Fin-
land, Iceland, Norway and Sweden) have conducted a pro-
spective population-based registration of all cases of acute
leukemia in children. All patients are followed up annually
and no patient has been lost to follow-up. Patients from the
database were eligible for this study if: (1) ALL was diag-
nosed between 1 July 1981 and 1 January 1992, (2) the
first relapse occurred before 1 October 1994 and (3) BMT
from a matched family donor was performed before 1 Janu-
ary 1995. The last follow-up was in January 1997.
From July 1981 to December 1991 1668 cases of non-
B ALL were diagnosed in children between 1 and 15 years
of age. In the study period 562 relapses occurred (441 were
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early relapses occurring during or within 6 months of dis-
continuing maintenance therapy and 121 were late
relapses). Seventy-five children were allografted in CR2
with a family donor at a median of 5 months after relapse
(60 children after an early and 15 children after a late
relapse), 14 children received an unrelated bone marrow
transplant, and 44 children were autografted. The remainder
of the children (ie 429 patients) were treated with second-
line chemotherapy; from this group of patients we selected
the control group (150 children) after exclusion of: (1)
patients who were treated with any form of bone marrow
transplantation and (2) patients with a duration of the
second remission of ,2 months. For each BMT case, two
control children in CR2 treated with chemotherapy were
selected who matched with the following criteria: (1) time
of diagnosis, (2) T vs non-T ALL, (3) site of relapse, (4)
initial risk group, (5) sex and (6) relapse , or >6 months
after cessation of therapy. The duration of the second
remission had to be at least equal to the time from relapse
to BMT, plus 2 additional months.
Treatment
From July 1981 to June 1986: Remission in the standard
risk group (SR: defined as age >2 and ,10 years, total
white blood cell count ,20 · 109/l and no high risk criteria)
was induced with prednisolone (Pred), vincristine (Vcr). In
Finland and Sweden doxorubicin was added to the induc-
tion regimen, whereas Denmark, Iceland and Norway gave
l-asparaginase for 10 days immediately after induced
remission. In July 1984, l-asparaginase was added to the
induction treatment in Finland and Sweden. CNS prophy-
laxis was performed with three 24-h infusions of metho-
trexate of 0.5 or (after July 1984) 1.0 g/m2 and eight intra-
thecal doses of methotrexate (MTX). No cranial irrradiation
was given. Maintenance therapy included daily oral 6-mer-
captopurine and weekly oral methotrexate for 36 months
after diagnosis. No reinduction was given. In a Norwegian
pilot study intravenous MTX infusions and Vcr were added
to the maintenance therapy during the first year of treat-
ment.
In most of the children belonging to the intermediate risk
group (IR: defined as age >1 and ,2 years or >10 years
or total white blood cell count >20 and ,50 · 109/l and
no high risk criteria. From July 1984 children with WBC
10–20 · 109/l were ‘upgraded’ from the SR to the IR
group20) the induction and consolidation therapy was as in
the SR group. However, the maintenance treatment with
oral 6-Mp and MTX was intensified with pulses of Pred
and Vcr with or without doxorubicin or MTX during the
first year. The total duration of therapy was 2 years.
Children with high risk criteria (HR: defined as WBC
>50 or T-ALL, or mediastinal mass or CNS leukemia at
diagnosis or t(9;22) or t(4;11)) were treated in many differ-
ent ways using primarily the intensive regimens of Riehm
et al21 and Wollner et al22 for a total of 2 years.
From July 1986 to December 1991: Remission in the SR
group was induced and consolidated in the same way as
during period I, all children receiving Vcr, Pred and
doxorubicin followed by 10 days of l-asparaginase. Main-
tenance therapy included i.v. infusions of MTX and Vcr.
The IR groups were additionally given early intensifi-
cation with pulses of cyclophosphamide and cytosine arabi-
noside and late intensification with 4 weeks reinduction
therapy consisting of oral dexamethazone, Vcr, doxorubicin
and l-asparaginase. In one group (Denmark, Finland and
Sweden) 12–18 Gy cranial irradiation was given before oral
maintenance therapy with 6-Mp and MTX, whereas the
other group (Iceland and Norway) gave pulses of high-dose
MTX (HD-Mtx) and/or high-dose cytosine arabinoside
(HD-Ara-C) before oral maintenance therapy with 6-Mp
and MTX with repeated pulses of HD-MTX and Vcr and
Pred during the first year. The HR-children in period II
were treated with intensive national protocols in all five
countries. In Denmark, Finland, Iceland and Sweden treat-
ment was more or less adapted to the German HR-protocol
implying cranial irradiation. In Norway two different regi-
mens were used with HD-MTX without doxorubicin and
HD-MTX, HD-Ara-C with doxorubicin, both regimens
without cranial irradiation. In addition, some patients were
treated with bone marrow transplantation in first
remission.19
Reinduction therapy
No uniform relapse protocol was employed in the study
period. Reinduction therapy was mostly based on the BFM
relapse protocols23 or other intensive chemotherapy proto-
cols. There was no difference in the initial treatment
between children who later underwent BMT and those who
received chemotherapy only.
Bone marrow transplant procedure
The 75 patients treated with BMT in CR2 were transplanted
2–25 (median 5) months after relapse. Only five patients
were transplanted later than 8 months after relapse. Ninety
percent of the BMTs were performed in three centers
(Helsinki, Finland; Huddinge, Sweden and Copenhagen,
Denmark).
The conditioning regimen consisted of total body
irradiation (TBI) of 10–11.5 GY given in four daily frac-
tions plus cyclophosphamide (CY) 60 mg/kg/day on 2 con-
secutive days (61 patients), busulphan 16 mg/kg in 16 doses
and CY 60 mg/kg/day on 2 consecutive days (10 patients)
or other TBI containing regimens (four patients). The BMT
donor was an HLA-identical sibling in 57 cases, a parent
in 12 cases and another relative in six cases. Graft-versus-
host disease (GVHD) prophylaxis consisted of cyclosporin
A (CyA) in 39 patients, MTX + CyA in 28 patients, MTX
only in six patients and other regimens in two patients.24–26
Statistical methods
In the matching procedure each BMT patient was stratified
according to the criteria defined above. For each trans-
planted patient two control patients fulfilling the same
stratification criteria were randomly allocated from the
group of children with ALL in second remission who had
not been transplanted. The procedure was repeated for each
patient until 150 control patients had been selected. Statisti-
cal analyses were performed with the Statistical Package
BMT in CR2 childhood ALL
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according to the methods of Kaplan and Meier. The distri-
bution of P2.-EFS (probability of second event-free
survival) for the different subgroups was compared with
the log rank test. The limit of significance was P = 0.05 in
all analyses.
Results
Table 1 shows that it was possible from the Nordic ALL
data base to randomly assign a control group of children
in second remission which corresponded closely to the
BMT group with respect to the important prognostic para-
meters such as length of first remission, site of first relapse,
T-ALL, time period of treatment, and sex.
The treatment-related toxic death rate (acute mortality)
within 6 months of the BMT procedure was 14/75 (19%),
the main causes being pulmonary infections, sepsis, acute
GVHD and bleeding. In addition there were two late deaths
from sepsis and chronic GVHD, both in continued second
remission, among the BMT patients. There was no differ-
ence in toxic death rate between the first and the second
part of the study period, but there were only three toxic
deaths during the last 4 years of the study period. Five of
18 (28%) patients transplanted with marrow from family
donors other than HLA-matched siblings died of BMT-
Table 1 Distribution of selection criteria in the BMT patients and in
the matched controls
Allo BMT in Matched
CR2 controls
Time of first relapse
During therapy +6 months 60 120
.6 months after Tx 15 30
Site of first relapse
Bone marrow (BM– ) 63 126
CNS isolated 7 14
Testes isolated 5 10
Treatment period
7/81–6/86 42 84
7/86–12/91 33 66
Sex
Girls 27 54
Boys 48 96
Immunophenotype
Non-T, non-B, biphenotypic and precursor- 67 137
B ALL
T ALL 2 4
Unknown 6 9
Age
2–,6 years 40 80
6–,10 years 21 42
>10 years 14 28
Initial risk group
SR/IR 58 116
High risk 17 34
WBC at diagnosis
,50 64 123
50–,100 4 10
>100 7 17
Mean time of first remission (months) 26.9 27.7
related toxicity, whereas the toxic death rate was 16% when
a fully matched sibling was the donor; this difference was
not significant.
The leukemic relapse rate and the proportion in con-
tinued second remission were 22/75 (29%) and 37/75
(50%), respectively. The 22 relapses occurred at a median
of 9 months post-transplant, in 19 cases ,14 months post-
transplant and one isolated CNS relapse 41 months post-
transplant. Twenty-one of 22 relapsed children have died
of underlying disease apart from one boy with an isolated
testicular relapse occurring 12 months after BMT in 1987.
The 75 transplanted patients differed significantly from
their controls in probability of remaining in second
remission (P2.-EFS) (Figure 1) (0.40 vs 0.23, P = 0.02).
The P2.-EFS for the BMT group was not different between
the first and the second half of the study period, but there
was a trend for the control group to do better during the
first part of the study.
Children transplanted for bone marrow relapses had a
significantly higher probability of staying in second CR
compared with the control group (Figure 2) (0.35 vs 0.15,
P , 0.01), whereas there was no difference in children with
extramedullary relapses.
Children transplanted for early bone marrow relapse (,6
months after discontinuation of initial therapy) had a higher
P2.-EFS compared with the chemotherapy group (0.32 vs
0.11, P = 0.01) (Figure 3a), while there was no difference
in outcome between BMT and controls whose first bone
marrow relapse occurred later than 6 months after discon-
tinuation of maintenance therapy (0.42 vs 0.29, NS,
Figure 3b).
In the BMT group (n = 75) there was no difference in
P2.-EFS between early and late relapses in the BMT group
(0.41 vs 0.40).
For girls the P2.-EFS was higher after BMT compared
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Figure 1 Overall results. Probability of second event-free survival (P2.-
EFS) for BMT-treated children compared with controls (= children treated
with chemotherapy only).
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Figure 2 Probability of second event-free survival (P2.-EFS) for 63 chil-
dren with bone marrow relapse compared with 126 controls.
with controls (0.59 vs 0.28, P = 0.02), and also the outcome
for girls was better than for boys after BMT although the
difference was not significant (0.59 vs 0.30, P = 0.06, NS)
(data not shown).
The relapse rate was 50% (11/22) in children whose
GVHD prophylaxis consisted of both CyA and methotrex-
ate, whereas it was 31% (11/35) in children treated with
CyA only. This difference was not statistically signifi-
cant, however.
The initial white blood cell count, age, initial risk group
classification or high-dose therapy before BMT had no
influence on outcome after relapse in this study.
Discussion
Randomised studies between BMT and chemotherapy in
the treatment of relapsed acute lymphoblastic leukemia are
difficult to perform, and have not been published in chil-
dren. There are many unsolved questions as to the indi-
cations for BMT in this group of children.8,9,15 Suitable
HLA-matched sibling donors may only be found in about
20% of possible cases, some of which may never proceed
to transplantation.18 Therefore reports regarding the results
of BMT in second remission of ALL originate largely in
registry data,14 data from cooperative groups4,13 or small
single-institution reports, often with no control group3,10–12
or with a historical control group. There are two recent
reports of case–control studies comparing chemotherapy
with BMT.17,28
This population-based study was able to define a care-
fully matched control group with respect to all known prog-
nostic factors in relapsed ALL. No uniform protocol was
used for relapse therapy. The fact that selection of control
patients was also based on the time period of first-line ther-
apy ensured that the pre-transplant chemotherapy was com-
parable in the two study groups.
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Figure 3 Probability of second event-free survival (P2.-EFS) for early
(during or within 6 months after discontinuing initial therapy) and late
bone marrow relapses (>6 months after discontinuation of therapy) com-
pared with controls.
Our results indicate that there is an overall benefit of
allogeneic bone marrow transplantation in children with
ALL after first relapse when transplanted children were
compared with a closely matched control group (Figure 1).
Especially in children with early bone marrow relapse,
BMT seems to give a significantly better survival compared
to the group of children receiving chemotherapy only.
Similar results were also reported by the German BFM
group13 comparing transplanted children with all other
relapsed patients. However, the duration of first remission,
site of first relapse and sex were not taken into account in
the non-transplanted patients. Another report from the BFM
BMT in CR2 childhood ALL
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between 18 months from diagnosis to 6 months after dis-
continuation of maintenance treatment the outcome was
better after BMT as compared with a control group which
had been in second remission for the corresponding time
after relapse.17 Our results did not allow any conclusions
regarding the benefit of BMT in children with isolated
extramedullary relapses or initial T-ALL because of
small numbers.
In a selected group of children transplanted in second
remission Brochstein et al10 also found a tendency for a
better outcome when the first remission was longer than 24
months, in contrast to the report by Kersey et al.11
Children with early bone marrow relapses have a parti-
cularly poor prognosis when treated with chemotherapy
alone, with a chance of long-term second remission of 2–
20%.3–5,7 In this group of children allogeneic BMT seems
indicated as is also shown in the present study. Since
GVHD is presumed to contribute to a better relapse-free
survival in these patients,29–31 BMT using unrelated donors
may also be considered in children with early bone
marrow relapse.
In children with late relapse the P2.-EFS for chemo-
therapy is 30–50% depending on the site of relapse and
first- and second-line therapy.2,4,6,7 In the present study only
15 children with late relapses were transplanted, and we
were not able to show any benefit from BMT for children
with late relapse compared with chemotherapy only. How-
ever, there was a trend for BMT being slightly better. In
our opinion this was not due to selection bias among these
patients since the median time from diagnosis to BMT was
46 months and the median time from diagnosis to inclusion
as a control patient in the chemotherapy group was 47.5
months. Other reports have also failed to show any better
prognosis for late relapses treated with BMT compared
with chemotherapy.3,13,28 Considering the observed early
toxic death rate (TDR) of 18% in the group transplanted
with fully matched sibling donor marrow and the possible
long-term sequelae of the TBI containing conditioning regi-
men, the indication for BMT in children with late relapses
using a matched sibling donor remains relative and related
to the TDR, which has declined considerably during the
past 3–4 years. When choosing not to perform BMT in
second remission of ALL after late relapse one should also
consider the lower chance of inducing a third remission,
the increased risk of acute morbidity and mortality and of
leukemic relapse after BMT if postponed until the third
remission.
All the children in this report have been followed up for
at least 2 years post-transplant. Since 19/22 relapses post-
BMT occurred within 14 months of the procedure (median
9 months) the risk of further relapses in this study is con-
sidered small, and further events may largely be caused by
complications of chronic GVHD, which was not the focus
of the present study. In conclusion, the present study, in
accordance with others, indicates that allogeneic BMT with
an HLA-identical sibling or other family donor should be
performed in children relapsing in the bone marrow during
therapy or within 6 months of discontinuing therapy. The
poor outlook of these patients when treated with chemo-
therapy may also justify BMT with an unrelated donor
although this procedure is still regarded as experimental.
For relapses occurring later than 6–12 months after elec-
tive discontinuation of maintenance therapy, the present
study failed to demonstrate any significant impact of allo-
geneic BMT in overall survival, although post-BMT relapse
rates were significantly higher in the chemotherapy group.
Since the overall result after treatment for relapse is
highly dependent on the intensity of first-line therapy, the
result of BMT as compared with chemotherapy should
frequently be re-evaluated.
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